Mini livers can be printed within 90 days

A new study suggests mini livers can be successfully printed in the laboratory within 90 days. This could have profound implications for transplant patients around the world.

Scientists have successfully grown ‘mini livers’ in the laboratory in a breakthrough which could provide an alternative to organ transplant. [1]

Figures from the NHS suggest thousands of people’s lives [2] are being put at risk by the wait for organ transplant. For those living with organ failure, the wait for a suitable donor can be agonising.

Longevity.Technology: 3D bioprinting has tremendous potential for helping organ patients receive the life saving transplants they desperately need. While fully functioning organs still lie in the future, innovations such as this shows scientists are making rapid progress.

The answer, many believe, could lie in 3D bioprinting. Activity is accelerating rapidly as any reader of longevity will have noticed. Before Christmas, for example, we covered CELLINK’s new partnership with Made in Space on the International Space Station. Meanwhile, the University of Minho is spinning out a new bioprinting start-up.

In this latest breakthrough, researchers at the Human Genome and Stem Cell Research Center (HUG-CELL) successfully created hepatic organoids which perform all of the liver’s functions such as storage of vitamins, bile secretion, protein production and many others.

Their innovative approach allows them to produce the hepatic tissue within the laboratory in just 90 days and ensures tissue retains hepatic functions for longer than in previous studies.

The key has been how the cells were included in the boiling which produces tissue within the 3D printer. Rather than just printing cells individually, researchers managed to regroup them before printing and, as such, produced clumps of cells or spheroids. These constitute the tissue and allow it to retain functionality for longer.

Although still in relatively early stages, researchers hope this could pave the way to a new form of organ transplant in the near future.

“More stages have yet to be achieved until we obtain a complete organ, but we’re on the right track to highly promising results,” said Mayana Zatz, director of HUG-CELL. “In the very near future, instead of waiting for an organ transplant, it may be possible to take cells from the patient and reprogram them to make a new liver in the laboratory.”

While this study only produced ‘mini’ livers, researchers believe that, with further investment and research, they will be able to produce complete organs suitable for transplant, all within 90 days.

[1] https://eurekalert.org/pub_releases/2019-12/fda-rcf121719.php

[2] https://bit.ly/39H44yd

Image credit: Daniel Antonio/Agência FAPESP

 

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...